Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqCM - Delayed Quote USD

Alpha Tau Medical Ltd. (DRTS)

Compare
2.5000
-0.0100
(-0.40%)
At close: April 1 at 4:00:00 PM EDT
2.4400
-0.01
(-0.41%)
After hours: April 1 at 4:08:01 PM EDT
Loading Chart for DRTS
  • Previous Close 2.5100
  • Open 2.5400
  • Bid --
  • Ask --
  • Day's Range 2.4500 - 2.5400
  • 52 Week Range 1.7500 - 4.3870
  • Volume 30,762
  • Avg. Volume 92,515
  • Market Cap (intraday) 175.952M
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4500
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.75

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, together with its subsidiaries, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

www.alphatau.com

125

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DRTS

View More

Performance Overview: DRTS

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DRTS
19.35%
S&P 500 (^GSPC)
4.23%

1-Year Return

DRTS
13.79%
S&P 500 (^GSPC)
7.42%

3-Year Return

DRTS
76.28%
S&P 500 (^GSPC)
23.92%

5-Year Return

DRTS
75.25%
S&P 500 (^GSPC)
128.01%

Compare To: DRTS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DRTS

View More

Valuation Measures

Annual
As of 4/1/2025
  • Market Cap

    175.95M

  • Enterprise Value

    128.89M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.81

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -23.27%

  • Return on Equity (ttm)

    -43.16%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -31.75M

  • Diluted EPS (ttm)

    -0.4500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    59.6M

  • Total Debt/Equity (mrq)

    20.00%

  • Levered Free Cash Flow (ttm)

    -12.97M

Research Analysis: DRTS

View More

Company Insights: DRTS

Research Reports: DRTS

View More

People Also Watch